Evidence map›Paper›PMID 35986281›Full record

ArticleOrphanet journal of rare diseases2022

Is population frequency a useful criterion to assign pathogenicity to newly described mitochondrial DNA variants?

M Pilar Bayona-Bafaluy, Ester López-Gallardo, Sonia Emperador, David Pacheu-Grau, Julio Montoya, Eduardo Ruiz-Pesini

Open access · goldAbstract readLetter
In one paragraph

Article in Orphanet journal of rare diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

M Pilar Bayona-BafaluyDepartamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, 50009 and 50013, Zaragoza, Spain.
Ester López-GallardoDepartamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, 50009 and 50013, Zaragoza, Spain.
Sonia EmperadorDepartamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, 50009 and 50013, Zaragoza, Spain.
David Pacheu-GrauDepartamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, 50009 and 50013, Zaragoza, Spain.
Julio MontoyaDepartamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, 50009 and 50013, Zaragoza, Spain.
Eduardo Ruiz-PesiniDepartamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, 50009 and 50013, Zaragoza, Spain. eduruiz@unizar.es.ORCID 0000-0002-0269-7337
Universidad de Zaragoza · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Population frequency has been one of the most widely used criteria to help assign pathogenicity to newly described mitochondrial DNA variants. However, after sequencing this molecule in thousands of healthy individuals, it has been observed that a very large number of genetic variants have a very low population frequency, which has raised doubts about the utility of this criterion. By analyzing the genetic variation of mitochondrial DNA-encoded genes for oxidative phosphorylation subunits in 195,983 individuals from HelixMTdb that were not sequenced based on any medical phenotype, we show that rare variants are deleterious and, along with other criteria, population frequency is still a useful criterion to assign pathogenicity to newly described variants.

Indexed as

DNA, MitochondrialMitochondriaPhenotypeVirulenceDNA, MitochondrialMitochondrial DNAPathological variantsPopulation frequency

Identifiers

PMID35986281
PMCPMC9389834
OpenAlexW4292299002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.